返回Google圖書搜尋

Strategies and Logic of Controlled Automated Reperfusion of the Whole Body Following Circulatory Arrest U00a0

出版	2017
URL	http://books.google.com.hk/books?id=bNq2zQEACAAJ&hl=&source=gbs_api

註釋Strategies and Logic of Controlled automated reperfusion of the whole body following Circulatory arrest Trummer G, Benk C, Scherer C, Fu00f6rster K, Taunyane I, Heilmann C, Beyersdorf FIntroductionA generalized Ischemia/Reperfusion injury (IRI) occurs frequently in patients with circulatory arrest (CA) followed by cardiopulmonary resuscitation (CPR) causing high mortality and neurologic sequela in the rare survivors. Limiting IRI of the whole-body and the brain could therefore be a goal in the treatment of these patients. Hence a therapeutic regimen called u201ccontrolled automated reperfusion of the whole body (CARL)u201d has been evolved in an animal model over the recent 15 years, in order to define and evaluate optimized conditions of reperfusion to limit IRI after CA. This regimen has now been successfully applied also in humans undergoing extremely prolonged CPR. MethodsChronic experimental setting of n=200 pigs in 20 different groups, undergoing either 15 or 20 minutes of unprotected normothermic ischemia. Different conditions of reperfusion have been evaluated, focusing on mortality and neurologic recovery within 7 consecutive days. A therapeutic regimen regarding optimized reperfusion conditions has been extracted from the results. Based on the results of the animal-studies, transfer into human use has been approved by the ethics committee.ResultsIn selected experimental groups, survival and neurologic recovery after 15 minutes CA rates up to 100% with corresponding numbers of 90% survival and 90% neurologic recovery after 20 min CA. Application of CARL in n=13 patients with extremely prolonged CPR (duration: 51-120 min) allowed survival and complete cerebral recovery in 6/13 patients. ConclusionCountercating IRI by controlling conditions and the reperfusion solution may be an important key to improve survival and neurologic recovery in patients with CA. Therefore a therapeutic regimen called CARL has been evolved to meet this demand. First clinical results are in line with the extensive expertise from preceding animal experiments showing beneficial effects for the affected patients. Another clinical trial is currently under development and will start including patients in the year 2018.